Clinical Trial Update: Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating AMG 386 in combination with Paclitaxel for advanced recurrent epithelial ovarian cancer and related peritoneal cancers …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• AMG-386 (trebananib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Amgen | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED